Belgium· BE-AMP-SAM472257-00
Senshio 60 mg
A ospemifene product containing ospemifene, registered in Belgium by Shionogi Europe. The same ATC class is registered in 11 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Ospemifene is registered in 11 of 19 countries.
Countries holding a registration under ATC G03XC05 (ospemifene), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 6 of them publish a price we can compare per daily dose
Ospemifene · ATC G03XC05
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Ospemifene
- Manufacturer
- Shionogi Europe
- Country
- Belgium (BE)
- ATC code
- G03XC05
- ATC class
- Ospemifene
- Defined daily dose
- 60 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
52 interactions on record for ospemifene.
Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ospemifene · interactions on record
52 records
- 7 severe
- 45 moderate
Most severe, free to view
- Tranexamic acidB02AA02severe
- FluconazoleJ02AC01severe
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ospemifene in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSENSHIOShionogi B.V., Amsterdam
- SpainSENSHIO 60 MG COMPRIMIDOS RECUBIERTOS CON PELICULAShionogi B.V.
- FinlandSenshioShionogi B.V.
- IrelandSenshio 60 mg Film-coated tabletShionogi B.V.
- IcelandSenshioShionogi B.V.
- NetherlandsSenshio 60 mg filmomhulde tablettenShionogi B.V.
- PolandSenshioShionogi B.V.
- SwedenSenshio 60 mg Filmdragerad tablettShionogi B.V
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Senshio
- Liechtenstein · Senshio
- Norway · Senshio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1564a3e5-02c4-479e-be88-e9ae4adcfc1f GET /v1/drugs/1564a3e5-02c4-479e-be88-e9ae4adcfc1f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Senshio 60 mg",
"name_fr": "Senshio 60 mg",
"name_nl": "Senshio 60 mg",
"amp_code": "SAM472257-00",
"strengths": [
"60.0000",
"60.0000",
"1.8200",
"1.8200"
],
"pack_count": 3,
"substances": [
"Ospemifene",
"Lactose",
"Mannitol",
"Sodium Starch Glycolate (Type A)"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Ospemifene",
"authorisation_numbers": [
"EU/1/14/978/001",
"EU/1/14/978/002",
"EU/1/14/978/003"
]
}See everything about ospemifene.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.